Miniatura

Fitxers

649146.pdf (77.24 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-11-02

Llicència de publicació

cc-by (c) Cahn, Pedro et al., 2014
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/120846

Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study.

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.7448/IAS.17.4.19554

Resum

INTRODUCTION: Treatment with ritonavir-boosted protease inhibitors and nucleoside analogues frequently leads to rises in lipids, which might increase the cardiovascular risk. The aim of this study was to describe changes in lipid levels among HIV positive patients participating in the GARDEL study. MATERIALS AND METHODS: The GARDEL study compared the efficacy and safety of a dual therapy (DT) combination of LPV/r 400/100 mg BID+3TC 150 mg BID to a triple therapy (TT) with LPV/r 400/100 mg BID+3TC or FTC and a third investigator-selected NRTI in fixed-dose combination among HIV+ treatment naïve patients. We compared changes in lipid levels from baseline to week 48 in both arms. RESULTS: Patient's characteristics were well balanced regarding mean baseline total cholesterol (157 mg/dL DT, 154 mg/dL TT), triglycerides (142 mg/dL DT, 139 mg/Dl TT), LDL-C (94 mg/dL DT, 91 mg/dL TT) and HDL-C (36 mg/dL DT, 35 mg/dL TT). Changes in total cholesterol, LDL-C and HDL-C were higher in DT arm, compared to TT (32% DT vs 26% TT for cholesterol; 25% DT vs 16% TT for LDL and 33% DT vs 28% TT for HDL). Increase in triglycerides was higher in TT compared to DT (55% DT vs 92% TT) (Table 1). In TT arm LDL-C and total cholesterol elevations were lower among patients receiving TDF compared to those treated with ZDV or ABC. CONCLUSION: Changes in lipid parameters were observed in both arms. Albeit the increase was numerically higher for cholesterol (total and LDL-C) in DT arm while TT arm had higher increases in TG; no difference was observed when week 48 values were compared with the NCEP ATP III goals for cardiovascular risk reduction (1). So, the DT strategy, even missing the lipid-lowering effect observed with tenofovir, does not seem to add significant risk to patients treated with this novel strategy.

Matèries

Persones seropositives, Lípids de la sang, Metabolisme dels lípids

Matèries (anglès)

HIV-positive persons, Blood lipids, Lipid metabolism

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

CAHN, Pedro, VILLANUEVA, Andrade, ARRIBAS, José ramón, GATELL, José m., LAMA, Javier, NORTON, Michel, PATTERSON, Patricia, SIERRA MADERO, Juan, SUED, Omar, INÉS FIGUEROA, Maria, JOSÉ ROLÓN, Maria. Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study.. _Journal of the International AIDS Society_. 2014. Vol. 17, núm. 4 Suppl 3, pàgs. 19554. [consulta: 21 de gener de 2026]. ISSN: 1758-2652. [Disponible a: https://hdl.handle.net/2445/120846]

Exportar metadades

JSON - METS

Compartir registre